Next-Generation Sequencing Analysis of Circulating Tumor DNA

Oliver Zill
Published: Monday, Sep 26, 2016



Oliver Zill, data scientist, Guardant Health, discusses the somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.

In the analysis, it was also found that the positive predictive value for finding actionable variance is high across key biomarkers, Zill explains. Researchers are also detecting actionable emerging resistance via circulating tumor DNA, which usually emerges after a patient undergoes a biopsy.


Oliver Zill, data scientist, Guardant Health, discusses the somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.

In the analysis, it was also found that the positive predictive value for finding actionable variance is high across key biomarkers, Zill explains. Researchers are also detecting actionable emerging resistance via circulating tumor DNA, which usually emerges after a patient undergoes a biopsy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x